GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Quest Diagnostics Inc (NYSE:DGX) » Definitions » EPS without NRI

Quest Diagnostics (Quest Diagnostics) EPS without NRI

: $8.19 (TTM As of Dec. 2023)
View and export this data going back to 1996. Start your Free Trial

Quest Diagnostics's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $2.15. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $8.19.

During the past 12 months, Quest Diagnostics's average earnings per share (NRI) Growth Rate was 9.30% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -6.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 11.10% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Quest Diagnostics's EPS without NRI or its related term are showing as below:

DGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -6   Med: 12.5   Max: 92.1
Current: -6

During the past 13 years, Quest Diagnostics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 92.10% per year. The lowest was -6.00% per year. And the median was 12.50% per year.

DGX's 3-Year EPS without NRI Growth Rate is ranked worse than
61.85% of 173 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.2 vs DGX: -6.00

Quest Diagnostics's EPS (Diluted) for the three months ended in Dec. 2023 was $1.70. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $7.49.

Quest Diagnostics's EPS (Basic) for the three months ended in Dec. 2023 was $1.72. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $7.59.


Quest Diagnostics EPS without NRI Historical Data

The historical data trend for Quest Diagnostics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.13 10.47 15.55 7.97 8.71

Quest Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.98 1.78 2.30 1.96 2.15

Competitive Comparison

For the Diagnostics & Research subindustry, Quest Diagnostics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest Diagnostics PE Ratio without NRI Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Quest Diagnostics's PE Ratio without NRI falls into.



Quest Diagnostics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quest Diagnostics  (NYSE:DGX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Quest Diagnostics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Quest Diagnostics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest Diagnostics (Quest Diagnostics) Business Description

Traded in Other Exchanges
Address
500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Executives
Luis Diaz director C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138
Michael E Prevoznik officer: Corp VP, Legal & Compliance C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Catherine T. Doherty officer: SVP, Physician Services Bus. C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Timothy M Ring director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Mark E Delaney officer: SVP & Chief Commercial Officer 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Mark A Gardner officer: SVP of Molecular Gen & Oncol 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Patrick Plewman officer: SVP for Diagnostic Services 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Karthik Kuppusamy officer: SVP, Clinical Solutions 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Michael J Deppe officer: VP, Corp. Controller & CAO 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094
Samer Abdul Samad officer: Executive Vice President & CFO 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stephen H Rusckowski director, officer: President and CEO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Tracey Doi director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Gail R Wilensky director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Mark Guinan officer: Senior Vice President & CFO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel Stanzione director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094